TRST IS The Next One To Run Thru 12.00

TD Buys At Days End:

16:00:00

T

8.29

-0.21

208,600

7 TD Sec

65 Goldman

KQ

16:00:00

T

8.29

-0.21

150,600

7 TD Sec

65 Goldman

KQ

Next

This study exemplifies CannTrust's focus on medical research and its dedication to uncovering the medicinal value of its proprietary cannabis products, and how they can improve health and well-being for all. In addition to assessing ALS disease progression, the study will also look at the effects of CannTrust CBD oil capsules on a variety of outcome measures related to ALS such as spasticity, pain, weight loss and quality of life. The CBD strain which will be used in the study was developed by CannTrust from its proprietary genetics, meaning that the research results will be specific to the Company's CBD oil.

"With our medicinal cannabis experience and over 50,000 patients enrolled over the past five years, we continue to see the medical potential of the cannabis plant. We are committed to being international leaders in the generation of scientific evidence proving the medical benefits in treating a variety of indications. With hundreds of thousands of people living with ALS in Canada and globally, we continue to focus on improving peoples' lives around the world," says Peter Aceto, CEO of CannTrust. "We also thank PharmaCann for its expertise and assistance in importing our products to Australia, to make this study possible."

About CannTrustCannTrust, - a federally regulated licensed producer of medical and recreational cannabis - is leading the Canadian and global market in producing standardized cannabis products. Founded as Canada's only pharmacist-founded medical cannabis producer, CannTrust brings more than 40 years of pharmaceutical and healthcare experience to the medical cannabis industry. CannTrust currently operates its 450,000 sq. ft. Niagara Perpetual Harvest Facility. The 600,000 sq. ft. greenhouse expansion has begun and is fully funded. The industry's broadest product portfolio is prepared and packaged at the 60,000 sq. ft. manufacturing centre of excellence in Vaughan, Ontario.

CannTrust is ready for Cannabis 2.0, and is currently developing new products for future verticals that span the medical, recreational, beauty, wellness and pet markets. CannTrust is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. Its product development teams and external partners are diligently innovating and developing products that will make it easier for patients to use medical cannabis. CannTrust supports ongoing patient education about medical cannabis and has a compassionate use program to support patients with financial needs.              

Forward Looking StatementsThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon CannTrust's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.

CannTrust Ships CBD Oil Capsules to Gold Coast University for Clinical Trial on Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND)

[26-November-2018]

VAUGHAN, ON, Nov. 26, 2018 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company") (TSX: TRST), one of Canada's leading and most trusted licensed producers of cannabis, announced today that it has shipped its standardized CBD oil capsules to Australia's Gold Coast University Hospital. The capsules will be used in a study to determine the efficacy of CannTrust CBD oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND), which was first announced by the Company in July 2018. The capsules will be imported, stored and distributed by PharmaCann Pty Ltd ("PharmaCann"). The shipment will include all investigational products that are required for the study. Trades for C:TRST on 20181126 - 100 trades displayed Time ET Ex Price Change Volume Buyer Seller Markers 16:01:08 X 8.30 -0.33 100 13 Instinet 99 Jitney 16:01:08 X 8.30 -0.33 400 13 Instinet 99 Jitney 16:00:00 T 8.29 -0.21 64 1 Anonymous 7 TD Sec Q 16:00:00 T 8.29 -0.21 17 1 Anonymous 7 TD Sec Q 16:00:00 T 8.29 -0.21 2,000 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 100 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 200 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 100 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 2,000 99 Jitney 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 1,000 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 2,600 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 3,800 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 8,400 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 200 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 1,000 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 3,000 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 500 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 1,900 1 Anonymous 39 Merrill Lynch KQ 16:00:00 T 8.29 -0.21 100 1 Anonymous 79 CIBC KQ 16:00:00 T 8.29 -0.21 500 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 5,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 1,000 99 Jitney 65 Goldman KQ 16:00:00 T 8.29 -0.21 150,600 7 TD Sec 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,500 7 TD Sec 7 TD Sec KQ 16:00:00 T 8.29 -0.21 300 99 Jitney 65 Goldman KQ 16:00:00 T 8.29 -0.21 10,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 600 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,000 13 Instinet 65 Goldman KQ 16:00:00 T 8.29 -0.21 5,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,700 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 300 13 Instinet 65 Goldman KQ 16:00:00 T 8.29 -0.21 3,000 13 Instinet 65 Goldman KQ 16:00:00 T 8.29 -0.21 1,500 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 1,800 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 10,000 2 RBC 65 Goldman KQ 16:00:00 T 8.29 -0.21 700 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 1,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,500 13 Instinet 65 Goldman KQ 16:00:00 T 8.29 -0.21 100 53 Morgan Stanley 65 Goldman KQ 16:00:00 T 8.29 -0.21 208,600 7 TD Sec 65 Goldman KQ 16:00:00 T 8.29 -0.21 1,000 1 Anonymous 65 Goldman KQ 16:00:00 T 8.29 -0.21 2,300 2 RBC 65 Goldman KQ 16:00:00 T 8.29 -0.21 300 1 Anonymous 65 Goldman KQ 15:59:59 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:59 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:59 T 8.22 -0.28 200 79 CIBC 65 Goldman K 15:59:59 T 8.22 -0.28 100 79 CIBC 65 Goldman K 15:59:59 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:59 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:55 O 8.22 -0.28 100 1 Anonymous 65 Goldman K 15:59:55 T 8.22 -0.28 100 53 Morgan Stanley 39 Merrill Lynch K 15:59:55 T 8.22 -0.28 100 53 Morgan Stanley 39 Merrill Lynch K 15:59:54 T 8.22 -0.28 100 1 Anonymous 39 Merrill Lynch K 15:59:54 T 8.22 -0.28 100 1 Anonymous 39 Merrill Lynch K 15:59:51 A 8.22 -0.28 100 1 Anonymous 65 Goldman K 15:59:48 O 8.22 -0.28 100 80 National Bank 65 Goldman K 15:59:45 H 8.20 -0.30 100 79 CIBC 85 Scotia K 15:59:44 A 8.21 -0.29 100 79 CIBC 65 Goldman K 15:59:44 T 8.22 -0.28 15 79 CIBC 7 TD Sec 15:59:44 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:44 T 8.26 -0.24 500 79 CIBC 7 TD Sec K 15:59:44 T 8.26 -0.24 100 79 CIBC 1 Anonymous K 15:59:44 T 8.24 -0.26 100 79 CIBC 2 RBC K 15:59:44 T 8.23 -0.27 1,000 79 CIBC 22 Fidelity K 15:59:44 T 8.23 -0.27 300 79 CIBC 89 Raymond James K 15:59:44 T 8.22 -0.28 100 79 CIBC 2 RBC K 15:59:44 T 8.22 -0.28 7,800 79 CIBC 39 Merrill Lynch K 15:59:44 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:44 T 8.22 -0.28 100 79 CIBC 39 Merrill Lynch K 15:59:44 T 8.22 -0.28 100 79 CIBC 79 CIBC K 15:59:44 T 8.21 -0.29 1,900 79 CIBC 99 Jitney K 15:59:43 O 8.21 -0.29 200 80 National Bank 65 Goldman K 15:59:40 A 8.19 -0.31 200 13 Instinet 65 Goldman K 15:59:40 A 8.19 -0.31 100 1 Anonymous 65 Goldman K 15:59:40 P 8.19 -0.33 25 1 Anonymous 7 TD Sec E 15:59:40 T 8.20 -0.30 100 1 Anonymous 1 Anonymous K 15:59:40 T 8.20 -0.30 100 80 National Bank 1 Anonymous K 15:59:40 T 8.19 -0.31 200 80 National Bank 65 Goldman K 15:59:37 O 8.19 -0.31 200 80 National Bank 65 Goldman K 15:59:37 T 8.19 -0.31 100 80 National Bank 65 Goldman K 15:59:36 T 8.21 -0.29 100 65 Goldman 99 Jitney K 15:59:34 A 8.17 -0.33 300 1 Anonymous 65 Goldman K 15:59:34 A 8.17 -0.33 100 1 Anonymous 65 Goldman K 15:59:34 U 8.17 -0.33 400 79 CIBC 79 CIBC K 15:59:34 U 8.17 -0.33 500 79 CIBC 79 CIBC K 15:59:34 P 8.17 -0.33 100 79 CIBC 79 CIBC K 15:59:34 H 8.17 -0.33 400 79 CIBC 39 Merrill Lynch K 15:59:34 H 8.17 -0.33 500 79 CIBC 79 CIBC K 15:59:34 O 8.17 -0.33 100 1 Anonymous 65 Goldman K 15:59:34 O 8.17 -0.33 300 1 Anonymous 1 Anonymous K 15:59:34 X 8.17 -0.33 300 79 CIBC 79 CIBC K 15:59:34 A 8.16 -0.34 2,700 79 CIBC 13 Instinet K 15:59:34 X 8.16 -0.34 200 79 CIBC 79 CIBC K 15:59:34 X 8.16 -0.34 100 79 CIBC 79 CIBC K 15:59:34 T 8.18 -0.32 100 53 Morgan Stanley 65 Goldman K 15:59:34 T 8.18 -0.32 100 79 CIBC 65 Goldman K 15:59:34 T 8.20 -0.30 100 53 Morgan Stanley 79 CIBC K 15:59:34 T 8.20 -0.30 300 1 Anonymous 79 CIBC K 15:59:34 T 8.20 -0.30 100 79 CIBC 2 RBC K